Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,012 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: matched placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

NCT01463098
View directory record Official record
Conditions
Insomnia
Interventions
E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Vitamin D Replacement on Insulin Sensitivity

NCT01268111
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Ergocalciferols, Placebo
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Asacol Acute Diverticulitis(DIVA)Study

NCT00554099
View directory record Official record
Conditions
Diverticulitis
Interventions
Mesalamine, Probiotic, Placebo, Dietary Advice, Antibiotic for Diverticulitis
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years to 85 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Merced, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 3 Interventional

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

NCT00331487
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Rosiglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
67
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 19, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional

Bempedoic Acid Therapy for Polycystic Kidney Disease

NCT07282821
View directory record Official record
Conditions
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions
Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s)
Drug
Lead sponsor
Kenneth Hallows
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Terminated Phase 3 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

NCT04251533
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
alpelisib, placebo, nab-paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Baton Rouge, Louisiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)

NCT02736409
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (OBS), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline

NCT01515098
View directory record Official record
Conditions
Mild Cognitive Decline
Interventions
Freeze-dried blueberries, Dextrose Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years to 79 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

NCT02669433
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
RVT-101 35 mg, RVT-101 70 mg, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

NCT00772538
View directory record Official record
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels

NCT07423598
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052
View directory record Official record
Conditions
Differentiated Thyroid Cancer (DTC)
Interventions
Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

NCT05684692
View directory record Official record
Conditions
Schwannomatosis, Schwannomas, Pain, Chronic
Interventions
Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

NCT06343298
View directory record Official record
Conditions
Difficult to Control Hypertension
Interventions
MANP, Placebo Matched control
Drug · Other
Lead sponsor
E-Star BioTech, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Little Rock, Arkansas • Lake Forest, California • Westlake Village, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

NCT06215521
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib, Placebo, Moxifloxacin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 19, 2026, 6:33 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

NCT04262206
View directory record Official record
Conditions
Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Interventions
Atorvastatin 40 Mg Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
75 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
104
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Not listed Not applicable Interventional

C15:0 Supplementation in Young Adults at Risk for Metabolic Syndrome

NCT04947176
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Jeffrey B. Schwimmer, MD
Other
Eligibility
18 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02301897
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Telapristone Acetate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

NCT05343455
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Santa Monica, California • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

NCT03259555
View directory record Official record
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Not applicable Interventional Results available

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients

NCT01433055
View directory record Official record
Conditions
Schizophrenia
Interventions
Minocycline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 19, 2026, 6:33 PM EDT
Terminated Phase 3 Interventional Results available

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

NCT04084678
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Recruiting Phase 3 Interventional

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT07743450
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 2 Interventional

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

NCT01002950
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
ACU-4429, Matching placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 19, 2026, 6:33 PM EDT